127984-74-1CC(=O)O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=ODEXPIBGCLCPUHE-UISHROKMSA-NLanreotide Acetate is the acetate salt of a synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.
127984-74-1CHEMBL1201184Breastfeeding; Lactation; Milk, Human; Hormones; Antineoplastic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Lanreotide acetate
Ambiguous-DILI-concern
2
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
LANREOTIDE ACETATE
Somatostatin Analog [EPC]; Somatostatin Receptor Agonists [MoA]
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…